CRYOPORT INC (CYRX)

US2290503075 - Common Stock

8.49  +0.51 (+6.39%)

After market: 8.49 0 (0%)

Fundamental Rating

2

Taking everything into account, CYRX scores 2 out of 10 in our fundamental rating. CYRX was compared to 56 industry peers in the Life Sciences Tools & Services industry. The financial health of CYRX is average, but there are quite some concerns on its profitability. CYRX is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYRX had negative earnings in the past year.
In the past year CYRX has reported a negative cash flow from operations.
CYRX had negative earnings in each of the past 5 years.
In the past 5 years CYRX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of CYRX (-23.72%) is worse than 64.29% of its industry peers.
CYRX has a Return On Equity of -39.77%. This is in the lower half of the industry: CYRX underperforms 62.50% of its industry peers.
Industry RankSector Rank
ROA -23.72%
ROE -39.77%
ROIC N/A
ROA(3y)-13.69%
ROA(5y)-13.63%
ROE(3y)-24.78%
ROE(5y)-21.69%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 42.28%, CYRX perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
In the last couple of years the Gross Margin of CYRX has declined.
The Profit Margin and Operating Margin are not available for CYRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5Y-3.93%

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYRX has more shares outstanding
The number of shares outstanding for CYRX has been increased compared to 5 years ago.
Compared to 1 year ago, CYRX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.11, we must say that CYRX is in the distress zone and has some risk of bankruptcy.
CYRX has a worse Altman-Z score (-0.11) than 76.79% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that CYRX is not too dependend on debt financing.
The Debt to Equity ratio of CYRX (0.44) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC8.32%

2.3 Liquidity

CYRX has a Current Ratio of 5.70. This indicates that CYRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.70, CYRX is doing good in the industry, outperforming 78.57% of the companies in the same industry.
A Quick Ratio of 5.32 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a better Quick ratio (5.32) than 80.36% of its industry peers.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.32

More info and screens

4

3. Growth

3.1 Past

CYRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -81.42%.
Looking at the last year, CYRX shows a decrease in Revenue. The Revenue has decreased by -4.34% in the last year.
Measured over the past years, CYRX shows a very strong growth in Revenue. The Revenue has been growing by 64.10% on average per year.
EPS 1Y (TTM)-81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.55%
Revenue 1Y (TTM)-4.34%
Revenue growth 3Y43.64%
Revenue growth 5Y64.1%
Sales Q2Q%0.9%

3.2 Future

The Earnings Per Share is expected to grow by 16.79% on average over the next years. This is quite good.
Based on estimates for the next years, CYRX will show a small growth in Revenue. The Revenue will grow by 4.31% on average per year.
EPS Next Y-2.23%
EPS Next 2Y23.77%
EPS Next 3Y16.79%
EPS Next 5YN/A
Revenue Next Year-3.01%
Revenue Next 2Y2.31%
Revenue Next 3Y4.31%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYRX. In the last year negative earnings were reported.
Also next year CYRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CYRX's earnings are expected to grow with 16.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.77%
EPS Next 3Y16.79%

More info and screens

0

5. Dividend

5.1 Amount

CYRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (1/3/2025, 8:00:01 PM)

After market: 8.49 0 (0%)

8.49

+0.51 (+6.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners112.8%
Inst Owner Change-2.51%
Ins Owners2.5%
Ins Owner Change7.17%
Market Cap419.66M
Analysts76.47
Price Target11.53 (35.81%)
Short Float %4.57%
Short Ratio5.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.47%
Min EPS beat(2)27.66%
Max EPS beat(2)93.29%
EPS beat(4)2
Avg EPS beat(4)-59.74%
Min EPS beat(4)-338.78%
Max EPS beat(4)93.29%
EPS beat(8)4
Avg EPS beat(8)-39.75%
EPS beat(12)5
Avg EPS beat(12)-33.52%
EPS beat(16)6
Avg EPS beat(16)-35.6%
Revenue beat(2)0
Avg Revenue beat(2)-3.2%
Min Revenue beat(2)-4.29%
Max Revenue beat(2)-2.11%
Revenue beat(4)0
Avg Revenue beat(4)-4.8%
Min Revenue beat(4)-8.91%
Max Revenue beat(4)-2.11%
Revenue beat(8)1
Avg Revenue beat(8)-3.09%
Revenue beat(12)1
Avg Revenue beat(12)-4.19%
Revenue beat(16)5
Avg Revenue beat(16)-1.35%
PT rev (1m)-0.29%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.43%
EPS NY rev (1m)0%
EPS NY rev (3m)10.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.86
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 2.22
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS4.57
BVpS8.47
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.72%
ROE -39.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.28%
FCFM N/A
ROA(3y)-13.69%
ROA(5y)-13.63%
ROE(3y)-24.78%
ROE(5y)-21.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5Y-3.93%
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.94%
Cap/Sales 12.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.32
Altman-Z -0.11
F-Score3
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)131.04%
Cap/Depr(5y)142.93%
Cap/Sales(3y)13.56%
Cap/Sales(5y)13.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.55%
EPS Next Y-2.23%
EPS Next 2Y23.77%
EPS Next 3Y16.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.34%
Revenue growth 3Y43.64%
Revenue growth 5Y64.1%
Sales Q2Q%0.9%
Revenue Next Year-3.01%
Revenue Next 2Y2.31%
Revenue Next 3Y4.31%
Revenue Next 5YN/A
EBIT growth 1Y-30.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.81%
EBIT Next 3Y29.88%
EBIT Next 5YN/A
FCF growth 1Y-33.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-189.27%
OCF growth 3YN/A
OCF growth 5YN/A